Loading...
KOD logo

Kodiak Sciences Inc.NasdaqGM:KOD 주식 보고서

시가총액 US$2.6b
주가
US$39.85
US$63.33
37.1% 저평가 내재 할인율
1Y864.9%
7D-5.7%
포트폴리오 가치
​
보기

Kodiak Sciences Inc.

NasdaqGM:KOD 주식 리포트

시가총액: US$2.6b

Kodiak Sciences (KOD) 주식 개요

임상 단계의 바이오 제약 회사인 코디악 사이언스는 망막 질환 치료를 위한 치료제의 연구, 개발 및 상용화에 종사하고 있습니다. 자세히 보기

KOD 펀더멘털 분석
스노우플레이크 점수
가치 평가3/6
미래 성장2/6
과거 실적0/6
재무 건전성5/6
배당0/6

강점

공정 가치 추정치보다 낮은 88.8% 에서 거래

수익은 연간 60.37% 증가할 것으로 예상됩니다.

분석가들은 주가가 58.9% 상승할 것이라는 데 동의합니다.

위험 분석

cash runway 경력이 1년 미만입니다.

수익이 USD$1m 미만입니다($0)

지난 3개월 동안 주가 변동성이 US 시장과 비교했을 때 매우 높았습니다.

현재 수익성이 없으며 향후 3년 동안 수익을 낼 것으로 예상되지 않습니다.

+ 위험 1건 추가

KOD Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Kodiak Sciences Inc. 경쟁사

가격 이력 및 성과

Kodiak Sciences 주가의 최고가, 최저가 및 변동 요약
과거 주가
현재 주가US$39.85
52주 최고가US$47.84
52주 최저가US$2.81
베타2.32
1개월 변동-7.56%
3개월 변동70.88%
1년 변동864.89%
3년 변동656.17%
5년 변동-52.90%
IPO 이후 변동292.22%

최근 뉴스 및 업데이트

Seeking Alpha • Mar 27

Kodiak Sciences: Shares Up On Positive Eye Disease Data - But I Remain On Sidelines

Summary Kodiak Sciences (KOD) surged after positive Phase 3 GLOW2 data for Zenkuda in diabetic retinopathy, demonstrating strong efficacy and risk reduction. KOD plans BLA submissions for Zenkuda across DR, RVO, and Wet AMD, targeting a $15bn market dominated by Roche and Regeneron, with less frequent dosing as a differentiator. Despite robust clinical progress and a 1,300% one-year rally, I maintain a Hold rating due to funding needs, potential dilution, and a congested competitive landscape. Market adoption risks, incumbent strength, and possible near-term fundraising temper enthusiasm, even as pipeline data continues to impress. Read the full article on Seeking Alpha

Recent updates

Seeking Alpha • Mar 27

Kodiak Sciences: Shares Up On Positive Eye Disease Data - But I Remain On Sidelines

Summary Kodiak Sciences (KOD) surged after positive Phase 3 GLOW2 data for Zenkuda in diabetic retinopathy, demonstrating strong efficacy and risk reduction. KOD plans BLA submissions for Zenkuda across DR, RVO, and Wet AMD, targeting a $15bn market dominated by Roche and Regeneron, with less frequent dosing as a differentiator. Despite robust clinical progress and a 1,300% one-year rally, I maintain a Hold rating due to funding needs, potential dilution, and a congested competitive landscape. Market adoption risks, incumbent strength, and possible near-term fundraising temper enthusiasm, even as pipeline data continues to impress. Read the full article on Seeking Alpha
분석 기사 • Oct 03

We're Keeping An Eye On Kodiak Sciences' (NASDAQ:KOD) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. By way of example, Kodiak...
Seeking Alpha • Feb 24

Kodiak Sciences: Anti-VEGF Could Win Nicely On Retinal Disorders

Summary Kodiak Sciences basically uses a novel biopolymer conjugate platform to develop more durable, next-generation retinal disease therapies. Today, KOD’s pipeline includes Phase 3 candidates for DR, RVO, and wet AMD, targeting an $18 billion TAM by 2028. The main catalyst to watch now is their upcoming pivotal data in 2026 that could lead to FDA approval by 2027. KOD also recently partnered up with Nona Biosciences to enhance its ability to develop multi-target, human monoclonal antibodies. From a valuation perspective, I also think KOD trades near cash value with a strong runway into 2026. So, I believe it’s a decent “Buy” at these levels. Read the full article on Seeking Alpha
분석 기사 • Dec 13

We're Keeping An Eye On Kodiak Sciences' (NASDAQ:KOD) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Nov 15

Kodiak: Tarcocimab Faces High Barriers To Entry Despite Resurrection (Rating Upgrade)

Summary Kodiak's stock surged 160% since September 2023, despite initial setbacks with tarcocimab in diabetic macular edema studies due to unexpected cataract development. Tarcocimab showed superiority over sham and better tolerability in a Phase 3 diabetic retinopathy trial, prompting Kodiak to resurrect the asset and initiate more pivotal trials. My previous recommendation was "sell" due to high risk and limited upside, but recent positive data and clinical advancements warrant a reassessment. KOD merits a "hold" ahead of key developments in their clinical trials, but this isn't for the faint of heart and works best within a barbell portfolio. Read the full article on Seeking Alpha
분석 기사 • Aug 02

We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
분석 기사 • Apr 17

We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
분석 기사 • Dec 29

We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
분석 기사 • Sep 09

We're Keeping An Eye On Kodiak Sciences' (NASDAQ:KOD) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
분석 기사 • May 26

Is Kodiak Sciences (NASDAQ:KOD) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
분석 기사 • Jan 04

We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
분석 기사 • Sep 25

Here's Why We're Watching Kodiak Sciences' (NASDAQ:KOD) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Aug 25

GreenWood Investors - Kodiak Sciences: The Busted Biotech World

Summary Kodiak Sciences busted earlier this year as its first of six pivotal Phase 3 trials on its lead compound, tarcocimab, failed its very poorly designed clinical trial. Subsequent to us taking a stake, Kodiak announced positive data on its most recent registration trial BEACON. Shares have perked up since announcing the BEACON top line data. We are well-aligned with the insiders at the company and the improving fundamentals, we can’t really just “sit this out,” until market conditions improve. The following segment was excerpted from this fund letter. Kodiak Sciences (KOD) A great example of companies that can perform in any environment is busted biotech world. One of the sectors undergoing the most pain in the recent year has been biotech, where we have invested in since 2004. Subsequent to the quarter end, we added a second company to our portfolio, and are actively engaged in researching more busted biotechs. Both our newest, Kodiak Sciences (KOD) and MEI Pharma (MEIP) have important regulatory catalysts in the very near future, and they have ample cash to get them through to the value inflection catalyst points. These are the types of names that can perform in any economic environment. The downside is protected by the cash position, and yes, while those cash positions are being spent on funding drug development, the long runways give us ample time to realize these value inflection milestones. We have been buyers of both companies as the market remains relatively indifferent to the looming regulatory updates. Kodiak Sciences busted earlier this year as its first of six pivotal Phase 3 trials on its lead compound, tarcocimab (formerly KSI-301), failed its very poorly designed clinical trial. The company’s drug will fill a significant unmet medical need, particular for diabetic and elderly patients with macular edema who have given up going to their doctor every 1-2 months to get their eye injected with Regeneron’s EYLEA. Industry research suggests that well over half of patients have chosen deteriorating vision over the inconvenience of getting their eyes injected every 1-2 months. That’s where tarcocimab comes in. In recent trials, even the “failed” trial, it has shown that 60-70% of patients can go five months or longer while maintaining the same significantly improved vision. While there are multiple therapies available for these patients, there are none that have the durability of tarcocimab. Subsequent to us taking a stake, Kodiak announced positive data on its most recent registration trial BEACON. Tarcocimab seeks to disrupt a $13 billion industry, but more importantly, fill an important gap in the macular edema market. In our conversations with doctors actively engaged in research & clinical trials, they are very eager to have a drug that they can dose less frequently. Shares have perked up since announcing the BEACON top line data, but given they still trade below cash levels, they give us a lot of upside as subsequent trials prove out that the drug works. Given the rest of the pivotal trials will read out in the next nine months, we won’t have to wait long until tarcocimab is able to serve the significant unmet medical need, and file for approval with the FDA next year. We also expect a very important update to MEIP’s regulatory strategy which will alleviate market concerns on its own drug’s timeliness to market. While many catalysts depend on a healthy market environment to play out, these do not. They can perform in any economic scenario. Trying to predict with accuracy when the stock will reflect the underlying developments is impossible. But we do know that if you miss the most material upside days of certain stocks, the realized returns are significantly more mediocre. To the extent we are well-aligned with the insiders at the company and the improving fundamentals, we can’t really just “sit this out,” until market conditions improve.
Seeking Alpha • Aug 07

Kodiak Sciences FQ1 2022 Earnings Preview

Kodiak Sciences (NASDAQ:KOD) is scheduled to announce FQ1 earnings results on Monday, August 8th, after market close. The consensus EPS Estimate is -$1.75 Over the last 3 months, EPS estimates have seen 0 upward revisions and 4 downward.
분석 기사 • May 18

Is Kodiak Sciences (NASDAQ:KOD) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • May 17

Kodiak Sciences: Potential For Comeback After Trial Setback

Results from the BEACON study, which is using KSI-301 for the treatment of patients with retinal vein occlusion, are expected by Q3 of 2022. The global retinal vein occlusion market is estimated to be worth $25.66 billion by 2028. Additional trial readouts using new dosing schedules such as diabetic macular edema, non-proliferative diabetic retinopathy, and treatment naive Wet-AMD are expected in 2023. Kodiak Sciences had $671.7 million in cash as of March 31, 2022, enough cash to fund operations for at least the next 12 months.
Seeking Alpha • Feb 25

Kodiak Sciences: KSI-301 Disappoints

Lead asset KSI-301 is being tested in six pivotal trials in retinal diseases including wet AMD, diabetic macular edema, retinal vein occlusion and non-proliferative diabetic retinopathy. Topline wet AMD data was released and KSI-301 failed to show non-inferiority against standard of care treatment Regeneron’s (REGN) Eylea in improvement in visual acuity. The study did not meet the primary endpoint. While KSI-301 appears safe and effective, it may not become a blockbuster.
Seeking Alpha • Feb 15

Highlighting Kodiak Sciences: A Great Buy Here Ahead Of Phase 3 Wet AMD Data For KSI-301 This Quarter

KSI-301 has shown higher retinal bioavailability and longer half-life than the comparator for this Phase 3 trial, the blockbuster drug Eylea (Aflibercept). Kodiak is attempting to prove non-inferiority in efficacy as shown by BCVA at 1 year vs. Eylea while showing the advantage of less frequent dosing. The first price target is $90 after positive data from the wet AMD Phase 3 trial this quarter or 70% upside potential in the stock (implied move from the options).
분석 기사 • Jan 24

We're Hopeful That Kodiak Sciences (NASDAQ:KOD) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
분석 기사 • Oct 11

Here's Why We're Not Too Worried About Kodiak Sciences' (NASDAQ:KOD) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Jul 19

Kodiak Sciences: Our Current Take On This Mid-Cap Biotech Company

Today, we look at a biotech firm who is developing a portfolio of retina therapeutics built on the company’s antibody biopolymer conjugate platform. Kodiak has late-stage drug candidate targeting wet age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and diabetic retinopathy. A full investment analysis is presented in the paragraphs below.

주주 수익률

KODUS BiotechsUS 시장
7D-5.7%0.1%2.6%
1Y864.9%35.5%26.2%

수익률 대 산업: KOD은 지난 1년 동안 35.5%의 수익을 기록한 US Biotechs 산업보다 더 좋은 성과를 냈습니다.

수익률 대 시장: KOD은 지난 1년 동안 26.2%를 기록한 US 시장보다 더 좋은 성과를 냈습니다.

주가 변동성

Is KOD's price volatile compared to industry and market?
KOD volatility
KOD Average Weekly Movement24.0%
Biotechs Industry Average Movement10.7%
Market Average Movement7.2%
10% most volatile stocks in US Market16.1%
10% least volatile stocks in US Market3.2%

안정적인 주가: KOD의 주가는 지난 3개월 동안 US 시장보다 변동성이 컸습니다.

시간에 따른 변동성: KOD의 주간 변동성(24%)은 지난 1년 동안 안정적이었지만 US 종목 중 상위 75%보다 높습니다.

회사 소개

설립직원 수CEO웹사이트
2009130Victor Perlrothkodiak.com

코디악사이언스는 임상 단계의 바이오 제약 회사로 망막 질환 치료를 위한 치료제의 연구, 개발 및 상용화에 종사하고 있습니다. 주요 제품 후보로는 유병률이 높은 망막 혈관 질환 치료를 위한 임상 3상 연구를 완료한 항혈관내피세포성장인자(VEGF) 항체 바이오폴리머인 타코시맙 테드로머(KSI-301)와 당뇨병성 망막증, 습성 연령 관련 황반변성(AMD), 망막정맥폐쇄, 당뇨황반부종 치료를 위한 임상 3상 및 습성 AMD 치료를 위한 임상 2/3상 연구를 진행 중인 타르코시맙 테드로머가 있으며, 현재 임상 3상을 진행 중입니다. 이 회사의 전임상 단계 제품 후보로는 유병률이 높은 망막 혈관 질환을 위한 항 인터루킨-6(IL-6) 및 VEGF-트랩 이중특이성 항체 바이오폴리머 접합체인 KSI-501과 망막액과 염증이 있는 환자를 위해 개발된 IL-6 및 VEGF를 표적으로 하는 이중특이성 단백질인 KSI-101(KSI-501P) 등이 있습니다.

Kodiak Sciences Inc. 기초 지표 요약

Kodiak Sciences의 순이익과 매출은 시가총액과 어떻게 비교됩니까?
KOD 기초 통계
시가총액US$2.56b
순이익 (TTM)-US$230.66m
매출 (TTM)n/a
0.0x
주가매출비율(P/S)
-10.8x
주가수익비율(P/E)

KOD는 고평가되어 있습니까?

공정 가치 및 평가 분석 보기

순이익 및 매출

최근 실적 보고서(TTM)의 주요 수익성 지표
KOD 손익계산서 (TTM)
매출US$0
매출원가US$0
총이익US$0
기타 비용US$230.66m
순이익-US$230.66m

최근 보고된 실적

Mar 31, 2026

다음 실적 발표일

해당 없음

주당순이익(EPS)-3.69
총이익률0.00%
순이익률0.00%
부채/자본 비율0%

KOD의 장기 실적은 어땠습니까?

과거 실적 및 비교 보기

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/05/11 06:10
종가2026/05/11 00:00
수익2026/03/31
연간 수익2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Kodiak Sciences Inc.는 18명의 분석가가 다루고 있습니다. 이 중 4명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
Anita DushyanthBerenberg
Matthew LuchiniBMO Capital Markets Equity Research
Ying HuangBofA Global Research